Bio-Techne vs IBM
Side-by-side comparison of AI visibility scores, market position, and capabilities
Minneapolis life science tools (NASDAQ: TECH) at $1.19B FY2024 revenue; Q2 FY2025 9% organic growth, R&D Systems cytokines/antibodies + RNAscope spatial biology (500K+ products) competing with Thermo Fisher for biopharma reagents.
About
Bio-Techne Corporation is a Minneapolis, Minnesota-based life sciences tools company — publicly traded on NASDAQ (NASDAQ: TECH) as an S&P 500 Health Care component — developing, manufacturing, and selling biological reagents, proteins, antibodies, assay kits, analytical instruments, and spatial biology tools for pharmaceutical drug discovery, bioprocessing, academic research, and clinical diagnostics through approximately 3,000 employees across 34 global locations with an annual revenue of $1.19 billion in fiscal year 2024. In Q2 fiscal 2025, Bio-Techne reported organic revenue growth of 9% to $297 million, demonstrating recovery from the funding-constrained biotech environment of 2023-2024. The company operates through two segments: Protein Sciences (approximately 75% of revenue, including the R&D Systems portfolio of 500,000+ life science products — cytokines, growth factors, antibodies, ELISAs, and recombinant proteins — as well as ProteinSimple analytical instruments and Tocris Bioscience chemical biology tools) and Diagnostics and Genomics (approximately 25%, including Advanced Cell Diagnostics' RNAscope technology for gene expression visualization in intact tissue and Lunaphore's COMET spatial biology automation platform acquired in 2023). Bio-Techne launched approximately 800 new products in fiscal 2024 and maintains a catalog of 6,000+ recombinant proteins spanning 35 species. The company has a market capitalization of approximately $9.59 billion.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
About
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
AI Visibility Head-to-Head
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.